Detalles de la búsqueda
1.
Antiretrovirals and Weight Change: Weighing the Evidence.
Clin Infect Dis;
2024 Apr 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38606799
2.
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.
Clin Infect Dis;
76(5): 861-870, 2023 03 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36259527
3.
Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 Trial.
Clin Infect Dis;
77(7): 991-1009, 2023 Oct 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37207617
4.
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.
J Antimicrob Chemother;
78(9): 2361-2365, 2023 09 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37539492
5.
FRAX assessment in people ageing with HIV.
HIV Med;
23(1): 103-108, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34541758
6.
Factors associated with overweight/obesity in a cohort of people living with HIV over 50 years of age.
AIDS Care;
34(4): 542-544, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34082628
7.
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV.
J Antimicrob Chemother;
76(9): 2380-2393, 2021 08 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34120186
8.
The benefits of tenofovir discontinuation with or without bisphosphonate therapy in osteoporotic people living with HIV.
HIV Med;
22(9): 816-823, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34258828
9.
Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics.
J Antimicrob Chemother;
75(5): 1259-1266, 2020 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32011683
10.
Increased Dolutegravir Peak Concentrations in People Living With Human Immunodeficiency Virus Aged 60 and Over, and Analysis of Sleep Quality and Cognition.
Clin Infect Dis;
68(1): 87-95, 2019 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29771285
11.
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study.
Clin Infect Dis;
68(4): 597-606, 2019 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29912307
12.
Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge.
J Antimicrob Chemother;
72(7): 2035-2041, 2017 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28407075
13.
Dolutegravir and elvitegravir plasma concentrations following cessation of drug intake.
J Antimicrob Chemother;
71(4): 1031-6, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26679246
14.
Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study.
J Infect Dis;
211(8): 1279-87, 2015 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25371534
15.
Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation.
Antimicrob Agents Chemother;
59(10): 6080-6, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26195515
16.
Pharmacokinetics of once-daily doravirine over 72 h following drug cessation.
J Antimicrob Chemother;
75(6): 1658-1660, 2020 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32083675
17.
Virological efficacy of abacavir: systematic review and meta-analysis.
J Antimicrob Chemother;
69(12): 3169-80, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25074854
18.
Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers.
J Antimicrob Chemother;
69(7): 1911-5, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24610312
19.
Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
J Infect Dis;
208(1): 32-9, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23532097
20.
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial.
Lancet HIV;
11(3): e156-e166, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38417976